The Cutaneous Lupus Erythematosus drugs in development market research report provides comprehensive information on the therapeutics under development for Cutaneous Lupus Erythematosus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Cutaneous Lupus Erythematosus. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Cutaneous Lupus Erythematosus and features dormant and discontinued products.
GlobalData tracks 17 drugs in development for Cutaneous Lupus Erythematosus by 16 companies/universities/institutes. The top development phase for Cutaneous Lupus Erythematosus is phase ii with eight drugs in that stage. The Cutaneous Lupus Erythematosus pipeline has 17 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Cutaneous Lupus Erythematosus pipeline products market are: Bristol-Myers Squibb, Daiichi Sankyo and Gilead Sciences.
The key targets in the Cutaneous Lupus Erythematosus pipeline products market include Toll-Llike Receptor 7, Toll Like Receptor 8, and T Cell Surface Glycoprotein CD8 Alpha Chain.
The key mechanisms of action in the Cutaneous Lupus Erythematosus pipeline product include Toll-Llike Receptor 7 Antagonist with three drugs in Phase II. The Cutaneous Lupus Erythematosus pipeline products include four routes of administration with the top ROA being Subcutaneous and five key molecule types in the Cutaneous Lupus Erythematosus pipeline products market including Monoclonal Antibody, and Small Molecule.
Cutaneous Lupus Erythematosus overview
Cutaneous lupus erythematosus (CLE) is lupus affecting the skin. It is a diverse group of autoimmune connective tissue disorders localised to the skin that can be associated with systemic lupus erythematosus (SLE) to varying degrees. Cutaneous lupus erythematosus (CLE) is classified as Acute (ACLE), Subacute (SCLE), Intermittent (lupus tumidus) and chronic (CCLE) eg, discoid lupus (DLE), lupus profundus, chilblain lupus erythematosus.
For a complete picture of Cutaneous Lupus Erythematosus’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
